/Investor DB

Vertex Ventures HC — 2021 Investments

3 investments dated 2021 · listed companies and verified rows first · show all

Boundless Bioboundlessbio.comin𝕏NASDAQ: BOLDApr 2021

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in

BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in

Co-investorsARCH Venture PartnersNextech InvestRA CapitalWellington ManagementAlexandriaCity Hill Ventures+3 more

Neuspera Medical, Inc.neuspera.comin𝕏Series C · Jul 2021 · $65M

Neuspera Medical develops an integrated sacral neuromodulation (iSNM) system that implants a smart neurostimulator near the sacral nerve to treat urinary urge incontinence, a symptom of overactive bladder.

BiotechHealthtechMedical DevicesSan Jose, US

Alexander Yeh(Founder)inMilton M. Morris(Executive Officer, Director)inDave Van Meter(Chief Executive Officer)Steve Paul(Chief Commercial Officer)in

Co-investorsAlumni VenturesCerity Partners VenturesForeground CapitalPortfoliaRH CapitalTreo Ventures, Llc+3 more

Sonoma Biotherapeuticssonomabio.comin𝕏Jul 2021

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)

Co-investors8VCARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)JDRF T1D FundLAV+6 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.